Business
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization.
About this update from Marijuana Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization\r\n \r\n \r\n\r\n\r\nExousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization\r\n\r\n\r\n\r\n\r\n\r\nORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce that it has executed a Letter of Intent to acquire a high-growth, established telehealth organization. Once acquired the Telehealth Platform will operate under Exousia Pro's newly-formed subsidiary, Exousia Health, Inc.\r\n This strategic transaction is designed to immediately generate substantial revenue, expand Exousia Pro's network, and create an unparalleled, cost-effective sales channel for its advanced nutraceutical and diagnostic products.\r\n Immediate Revenue Impact and Growth Projections\r\n The platform enters the portfolio with a solid financial base of approximately $80,000 in monthly recurring revenue. Furthermore, Exousia Health immediately gains control of a significant, established contract that designates the platform as the exclusive supplier of Testosterone across a robust network of 1,900 clinics. This high-impact agreement is slated to begin in February 2026 and is conservatively projected to add $2.4 million in annual revenue, based on projected fulfillment of 2,000 daily scripts over a 300-day service year.\r\n Overall, the acquisition is expected to position Exousia Health for robust financial performance, with the company projecting to achieve a net income of $3.0 million in fiscal year 2026.\r\n Powerful Synergy: Accelerating Shareholder Value\r\n The primary strategic benefit of this acquisition lies in the ability of Exousia Health to immediately leverage the telehealth group's existing network and large, specialized client base which includes individuals highly invested in wellness, anti-aging, and regenerative treatments.\r\n This established client funnel is perfectly aligned with Exousia Pro's product pipeline, particularly the recently launched Maxasome™ exosomal nutraceutical.\r\n \r\n Cost-Effective Client Acquisition: By utilizing the...